drugset / Trial / NCT06092931
A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
Phase 1
Completed
28 enrolled
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The main objective of this study is to assess the effect of DC-806 on the pharmacokinetics (PK) of cytochrome 3A4 (CYP3A4) substrate, midazolam and its active metabolite, 1-hydroxymidazolam, cytochrome 2C8 (CYP2C8) substrate repaglinide, P-glycoprotein (P-gp) transporter substrate digoxin, and breast cancer resistant protein (BCRP)/ organic anion transporter protein-1B1 (OATP1B1) transporter substrate rosuvastatin in healthy participants.
Timeline
- Start
- 2023-10-16
- Primary completion
- 2023-11-28
- Completion
- 2023-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC-806 | Unknown | — | Oral |
| Subject | Digoxin | Other / unclassified | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |
| Subject | Repaglinide | Small molecule | — | Oral |
| Subject | Rosuvastatin | Small molecule | — | Oral |
Indications
No indication recorded.